Literature DB >> 11931609

Biological activity of the tryprostatins and their diastereomers on human carcinoma cell lines.

Shuo Zhao1, Kirsten S Smith, Amy Morin Deveau, Christine M Dieckhaus, Michael A Johnson, Timothy L Macdonald, James M Cook.   

Abstract

Tryprostatin A 1 and B 2 are indole alkaloid-based fungal products that act in the G2/M phase of the cell cycle. Tryprostatin A and B as well as their two enantiomers and four diastereomers have been synthesized via a common strategy. As a measure of cytotoxicity, these eight stereoisomers were assayed for their growth inhibitory properties in human breast, prostate, and lung cancer cell lines. The ability of the tryprostatins and the tryprostatin stereoisomers to induce topoisomerase II-mediated DNA relaxation or to inhibit tubulin polymerization was also examined. Although none of the stereoisomers were significantly active in topoisomerase II- or tubulin-based assays, ds2-try B 11 was found to exhibit a cytotoxicity profile more potent than etoposide 3 in the human cancer cell lines examined. In addition, ds2-try B 11 is comprised of an L-tryptophan derivative coupled to a D-proline moiety, the latter stereochemistry of which may enhance the activity of 11 and potential analogues in vivo.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11931609     DOI: 10.1021/jm0155953

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  15 in total

Review 1.  Structure and noncanonical chemistry of nonribosomal peptide biosynthetic machinery.

Authors:  Heather L Condurso; Steven D Bruner
Journal:  Nat Prod Rep       Date:  2012-06-25       Impact factor: 13.423

Review 2.  Can nanomedicines kill cancer stem cells?

Authors:  Yi Zhao; Daria Y Alakhova; Alexander V Kabanov
Journal:  Adv Drug Deliv Rev       Date:  2013-10-10       Impact factor: 15.470

3.  Biochemical characterization of a novel indole prenyltransferase from Streptomyces sp. SN-593.

Authors:  Shunji Takahashi; Hiroshi Takagi; Atsushi Toyoda; Masakazu Uramoto; Toshihiko Nogawa; Masashi Ueki; Yoshiyuki Sakaki; Hiroyuki Osada
Journal:  J Bacteriol       Date:  2010-03-26       Impact factor: 3.490

4.  ABCG2 expression, function, and promoter methylation in human multiple myeloma.

Authors:  Joel G Turner; Jana L Gump; Chunchun Zhang; James M Cook; Douglas Marchion; Lori Hazlehurst; Pamela Munster; Michael J Schell; William S Dalton; Daniel M Sullivan
Journal:  Blood       Date:  2006-08-17       Impact factor: 22.113

5.  Unraveling terminal C-domain-mediated condensation in fungal biosynthesis of imidazoindolone metabolites.

Authors:  Stuart W Haynes; Brian D Ames; Xue Gao; Yi Tang; Christopher T Walsh
Journal:  Biochemistry       Date:  2011-06-02       Impact factor: 3.162

Review 6.  Recent Advances in the Synthesis of Marine-Derived Alkaloids via Enzymatic Reactions.

Authors:  Bi-Shuang Chen; Di Zhang; Fayene Zeferino Ribeiro de Souza; Lan Liu
Journal:  Mar Drugs       Date:  2022-05-30       Impact factor: 6.085

Review 7.  Synthesis of indole derivatives as prevalent moieties present in selected alkaloids.

Authors:  Majid M Heravi; Zahra Amiri; Kosar Kafshdarzadeh; Vahideh Zadsirjan
Journal:  RSC Adv       Date:  2021-10-15       Impact factor: 4.036

8.  Ethyl 1-acetyl-1H-indole-3-carboxyl-ate.

Authors:  Tasneem Siddiquee; Shahid Islam; Dennis Bennett; Matthias Zeller; Mahmun Hossain
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-07-08

9.  Synthesis and structure-activity relationship studies on tryprostatin A, an inhibitor of breast cancer resistance protein.

Authors:  Hiteshkumar D Jain; Chunchun Zhang; Shuo Zhou; Hao Zhou; Jun Ma; Xiaoxiang Liu; Xuebin Liao; Amy M Deveau; Christine M Dieckhaus; Michael A Johnson; Kirsten S Smith; Timothy L Macdonald; Hideaki Kakeya; Hiroyuki Osada; James M Cook
Journal:  Bioorg Med Chem       Date:  2008-02-20       Impact factor: 3.641

Review 10.  Pharmacological targets of breast cancer stem cells: a review.

Authors:  Sai Kiran S S Pindiprolu; Praveen T Krishnamurthy; Pavan Kumar Chintamaneni
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-02-23       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.